A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma

Sacco, J.J., Jackson, R., Corrie, P. et al. (18 more authors) (2024) A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 202. 114009. ISSN 0959-8049

Abstract

Metadata

Item Type: Article
Authors/Creators:
  • Sacco, J.J.
  • Jackson, R.
  • Corrie, P.
  • Danson, S. ORCID logo https://orcid.org/0000-0002-3593-2890
  • Evans, T.R.J.
  • Ochsenreither, S.
  • Kumar, S.
  • Goodman, A.
  • Larkin, J.
  • Karydis, I.
  • Steven, N.
  • Lorigan, P.
  • Plummer, R.
  • Patel, P.
  • Psarelli, E.
  • Olsson-Brown, A.
  • Shaw, H.
  • Leyvraz, S.
  • Handley, L.
  • Rawcliffe, C.
  • Nathan, P.
Copyright, Publisher and Additional Information:

© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords: MEK inhibitor; Metastatic uveal melanoma; Paclitaxel; Selumetinib
Dates:
  • Published: May 2024
  • Published (online): 11 March 2024
  • Accepted: 4 March 2024
  • Submitted: 22 December 2023
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Depositing User: Symplectic Sheffield
Date Deposited: 08 Apr 2024 09:38
Last Modified: 08 Apr 2024 09:38
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: 10.1016/j.ejca.2024.114009
Related URLs:
Open Archives Initiative ID (OAI ID):

Download

Export

Statistics